Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion.
Malarikova D, Jorda R, Kupcova K, Senavova J, Dolnikova A, Pokorna E, Kazantsev D, Nozickova K, Sovilj D, Bellanger C, Chiron D, Andera L, Krystof V, Strnad M, Helman K, Klanova M, Trneny M, Havranek O, Klener P. Malarikova D, et al. Among authors: bellanger c. Exp Hematol Oncol. 2024 Mar 25;13(1):34. doi: 10.1186/s40164-024-00499-2. Exp Hematol Oncol. 2024. PMID: 38528594 Free PMC article.
The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission.
Blaise D, Attal M, Pico JL, Reiffers J, Stoppa AM, Bellanger C, Molina L, Nedellec G, Vernant JP, Legros M, Gabus R, Huguet F, Brandely M, Hercend T, Olive D, Maraninchi D. Blaise D, et al. Among authors: bellanger c. Leuk Lymphoma. 1997 May;25(5-6):469-78. doi: 10.3109/10428199709039034. Leuk Lymphoma. 1997. PMID: 9250817 Clinical Trial.
Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma.
Herviou L, Ovejero S, Izard F, Karmous-Gadacha O, Gourzones C, Bellanger C, De Smedt E, Ma A, Vincent L, Cartron G, Jin J, De Bruyne E, Grimaud C, Julien E, Moreaux J. Herviou L, et al. Among authors: bellanger c. Clin Epigenetics. 2021 Sep 16;13(1):174. doi: 10.1186/s13148-021-01160-z. Clin Epigenetics. 2021. PMID: 34530900 Free PMC article.
A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics.
Durand R, Descamps G, Bellanger C, Dousset C, Maïga S, Alberge JB, Derrien J, Cruard J, Minvielle S, Lilli NL, Godon C, Le Bris Y, Tessoulin B, Amiot M, Gomez-Bougie P, Touzeau C, Moreau P, Chiron D, Moreau-Aubry A, Pellat-Deceunynck C. Durand R, et al. Among authors: bellanger c. Blood. 2024 Mar 28;143(13):1242-1258. doi: 10.1182/blood.2023021581. Blood. 2024. PMID: 38096363
Combined inhibition of CTPS1 and ATR is a metabolic vulnerability in p53-deficient myeloma cells.
Durand R, Bellanger C, Descamps G, Dousset C, Maïga S, Derrien J, Thirouard L, Bouard L, Asnagli H, Beer P, Parker A, Gomez-Bougie P, Devilder MC, Moreau P, Touzeau C, Moreau-Aubry A, Chiron D, Pellat-Deceunynck C. Durand R, et al. Among authors: bellanger c. Hemasphere. 2024 Oct 8;8(10):e70016. doi: 10.1002/hem3.70016. eCollection 2024 Oct. Hemasphere. 2024. PMID: 39380841 Free PMC article.
75 results